An International Leader in Pharmaceutical Excipients Kolkata, 13 June 2025: The biggest manufacturer of microcrystalline cellulose (MCC) in India, Sigachi Industries Ltd., is steadily raising the bar for pharmaceutical excipients
Bharat Biotech International Limited (BBIL) announces a strategic partnership with GSK plc to advance the development and distribution of the Shigella vaccine candidate, altSonflex1-2-3. Shigellosis, a serious bacterial...
Brenntag, the leading distributor of chemicals and additives worldwide, announced that it has acquired mcePharma in the Czech Republic. Brenntag's capabilities throughout the whole pharmaceutical
Biocon Foundation, the CSR arm of Biocon Group, has launched BioWISE – Women in STEM Empowered – a pioneering initiative to support women science students from underrepresented communities in Karnataka. In collaboration with The Bengaluru Scien...
Kyndryl, a top mission-critical enterprise technology services company, has entered into a strategic association with Dr. Reddy's Laboratories, a leading Indian multinational pharmaceutical firm, to transform and simplify the latter's worldwide IT
At the retail price previously authorized by the National Pharmaceutical Pricing Authority ( NPPA), Torrent Pharmaceuticals has been permitted to move the manufacturing of its combination medication for nutritional
A significant drop is being seen in the prices of active pharmaceutical ingredients (API) used for manufacturing drugs, bringing relief to India's pharmaceutical industry. China is largely depended upon the pharma industry for sourcing APIs
An agreement has been reached between BioNTech and Bristol Myers Squibb for the worldwide co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across a variety of solid tumor types.
The Authentication Solution Providers’ Association (ASPA) ahead of World Anti-Counterfeiting Day, has commissioned the second edition of its flagship industry report, ‘State of Counterfeiting in India – 2025
Aumolertinib (Aumseqa) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for adult patients with non-small cell lung cancer (NSCLC).
.jpg)
, CDSCO.jpg)